臨床前毒性試驗(yàn)或其他動(dòng)物試驗(yàn)中動(dòng)物出現(xiàn)疾病及死亡，是毒理學(xué)家和病理學(xué)家關(guān)心的重要問(wèn)題之一。動(dòng)物肺水腫臨床癥狀表現(xiàn)復(fù)雜，結(jié)合病理學(xué)改變確定肺水腫的發(fā)生原因，對(duì)其臨床前藥物安全性評(píng)價(jià)尤為重要。針對(duì)臨床前安全性評(píng)價(jià)實(shí)驗(yàn)中不同原因?qū)е聞?dòng)物肺水腫進(jìn)行闡述，對(duì)可能導(dǎo)致動(dòng)物肺水腫的原因進(jìn)行歸類、分析，并對(duì)其動(dòng)物的臨床癥狀表現(xiàn)及病理學(xué)改變的特點(diǎn)作進(jìn)一步的探討，為臨床前安全性評(píng)價(jià)結(jié)果提供更科學(xué)的判斷標(biāo)準(zhǔn)。

The occurrence of disease and death in preclinical toxicity test or other animal test is one of the important issues concerned by toxicologists and pathologists. The clinical symptoms of pulmonary edema in animals are complex. It is very important to evaluate the safety of drugs before clinical treatment to determine the cause of pulmonary edema combined with pathological changes. The causes of pulmonary edema in preclinical safety evaluation are been classified,discussed and analyzed in this paper and then clinical symptoms and pathological changes of experimental animals are been further discussed in order to provide more scientific judgment standards